Specific therapies for ischaemic stroke: rTPA and others

In the last few years there have been several important advances in the understanding of cerebrovascular disorder pathophysiology that have impacted on stroke management. The development of timely and effective treatment strategies was and is still considered a high priority issue. Therapeutic optio...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2005-05, Vol.26 Suppl 1 (S1), p.S26-s28
Main Authors: Toni, D, Lorenzano, S, Sacchetti, M L, Fiorelli, M, De Michele, M, Principe, M
Format: Article
Language:English
Subjects:
Brain Ischemia - drug therapy
Clinical Trials as Topic
Fibrinolytic Agents - therapeutic use
Humans
Neurology
Neurosciences
Stroke
Thrombolytic Therapy - methods
Time Factors
Tissue Plasminogen Activator - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the last few years there have been several important advances in the understanding of cerebrovascular disorder pathophysiology that have impacted on stroke management. The development of timely and effective treatment strategies was and is still considered a high priority issue. Therapeutic options dramatically increased both in the prevention and overall in the treatment of acute ischaemic stroke (AIS). At present, whereas neuroprotection remains experimental, intravenous (i.v.) thrombolysis is the only specific therapy effective in reducing mortality and disability associated with stroke. The efficacy and safety of the antithrombotic therapy in AIS treatment are not well established, and few issues in clinical stroke management are more controversial. However, some studies have brought new light and new doubts on the roles of these traditional therapies.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-005-0399-4